March 23rd 2023
The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.
February 28th 2023
Talazoparib/Enzalutamide Improves Imaging-Based PFS in Metastatic CRPC, Regardless of HRR Status
February 17th 2023At a median follow-up of 24.9 months, imaging-based progression-free survival was not reached among patients with metastatic castration-resistant prostate cancer who had received talazoparib plus enzalutamide.
Nivolumab/Ipilimumab May Be Most Effective mRCC Treatment, Sunitinib Most Cost-Effective
January 18th 2023A decision model with a 10-year time horizon found that nivolumab plus ipilimumab was the most effective combination for patients with metastatic renal cell carcinoma, but sunitinib was the most cost-effective approach.
Neoadjuvant Split-Dose Chemotherapy Represents Potential New Standard of Care for High-Risk UTUC
January 13th 2023Neoadjuvant treatment with gemcitabine and split-dose cisplatin followed by surgical resection and lymph node dissection proved to be effective and well-tolerated for patients with high-risk upper tract urothelial carcinoma.
Rogaratinib May Be Effective for Patients With Bladder Cancer and FGFR3 DNA Alterations
November 14th 2022Rogaratinib did not display a significant benefit over chemotherapy in patients with FGFR mutated bladder cancer, but the targeted treatment did generate encouraging responses among those with FGFR3 DNA alterations.
Adjuvant RCC Therapy Remains a Challenge as Treatment Landscape Continues to Evolve
November 3rd 2022Nancy Moldawer, RN, MSN, cochair of the Kidney Cancer Association's Clinical Advisory Board, speaks to unfolding data in the renal cell carcinoma space and the challenges in providing adjuvant therapy to this patient population.
Adding Cediranib to Olaparib Increases Treatment Efficacy, But Raises Toxicity Concerns, in mCRPC
October 29th 2022A regimen of cediranib and olaparib improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared with olaparib monotherapy. However, the rate of dose reductions was doubled with the combination.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28th 2022Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Real-World HRQOL Findings Support Nivolumab for Previously Treated mRCC
September 19th 2022Results of retrospective analysis of previously treated patients with metastatic renal cell carcinoma who received nivolumab in the second- and third-line showed that health-related quality of life was maintained in the real-world setting